YAP and the Hippo pathway in cholangiocarcinoma

Takaaki Sugihara, Hajime Isomoto, Gregory James Gores, Rory Smoot

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

Cholangiocarcinoma (CCA) has an increasing incidence and remains a difficult to treat malignancy. In a search for more effective treatment options, progress has been made in identifying molecular drivers of oncogenic signaling including IDH mutations and FGFR2 fusions. In addition, multiple investigators have identified increased activity of YAP, the effector protein of the Hippo pathway, in CCA. The Hippo pathway regulates organ size, cellular proliferation, and apoptosis via YAP, a transcriptional co-activator. Targeting of the pathway has been difficult due the lack of a dedicated cell-surface receptor. However, more recently, additional cross-regulatory pathways have been identified that are potentially targetable. In this review, we address the current treatment landscape for CCA, the Hippo pathway broadly, animal models of CCA with attention to Hippo-related models, and the current strategies for targeting YAP.

Original languageEnglish (US)
Pages (from-to)485-491
Number of pages7
JournalJournal of Gastroenterology
Volume54
Issue number6
DOIs
StatePublished - Jun 5 2019

Fingerprint

Cholangiocarcinoma
Organ Size
Cell Surface Receptors
Animal Models
Research Personnel
Cell Proliferation
Apoptosis
Mutation
Incidence
Neoplasms
Proteins

Keywords

  • Cholangiocarcinoma
  • Hippo pathway
  • Yes-associated protein

ASJC Scopus subject areas

  • Gastroenterology

Cite this

YAP and the Hippo pathway in cholangiocarcinoma. / Sugihara, Takaaki; Isomoto, Hajime; Gores, Gregory James; Smoot, Rory.

In: Journal of Gastroenterology, Vol. 54, No. 6, 05.06.2019, p. 485-491.

Research output: Contribution to journalReview article

Sugihara, Takaaki ; Isomoto, Hajime ; Gores, Gregory James ; Smoot, Rory. / YAP and the Hippo pathway in cholangiocarcinoma. In: Journal of Gastroenterology. 2019 ; Vol. 54, No. 6. pp. 485-491.
@article{3f93368c8c164ac7bee09b97df9e1892,
title = "YAP and the Hippo pathway in cholangiocarcinoma",
abstract = "Cholangiocarcinoma (CCA) has an increasing incidence and remains a difficult to treat malignancy. In a search for more effective treatment options, progress has been made in identifying molecular drivers of oncogenic signaling including IDH mutations and FGFR2 fusions. In addition, multiple investigators have identified increased activity of YAP, the effector protein of the Hippo pathway, in CCA. The Hippo pathway regulates organ size, cellular proliferation, and apoptosis via YAP, a transcriptional co-activator. Targeting of the pathway has been difficult due the lack of a dedicated cell-surface receptor. However, more recently, additional cross-regulatory pathways have been identified that are potentially targetable. In this review, we address the current treatment landscape for CCA, the Hippo pathway broadly, animal models of CCA with attention to Hippo-related models, and the current strategies for targeting YAP.",
keywords = "Cholangiocarcinoma, Hippo pathway, Yes-associated protein",
author = "Takaaki Sugihara and Hajime Isomoto and Gores, {Gregory James} and Rory Smoot",
year = "2019",
month = "6",
day = "5",
doi = "10.1007/s00535-019-01563-z",
language = "English (US)",
volume = "54",
pages = "485--491",
journal = "Journal of Gastroenterology",
issn = "0944-1174",
publisher = "Springer Japan",
number = "6",

}

TY - JOUR

T1 - YAP and the Hippo pathway in cholangiocarcinoma

AU - Sugihara, Takaaki

AU - Isomoto, Hajime

AU - Gores, Gregory James

AU - Smoot, Rory

PY - 2019/6/5

Y1 - 2019/6/5

N2 - Cholangiocarcinoma (CCA) has an increasing incidence and remains a difficult to treat malignancy. In a search for more effective treatment options, progress has been made in identifying molecular drivers of oncogenic signaling including IDH mutations and FGFR2 fusions. In addition, multiple investigators have identified increased activity of YAP, the effector protein of the Hippo pathway, in CCA. The Hippo pathway regulates organ size, cellular proliferation, and apoptosis via YAP, a transcriptional co-activator. Targeting of the pathway has been difficult due the lack of a dedicated cell-surface receptor. However, more recently, additional cross-regulatory pathways have been identified that are potentially targetable. In this review, we address the current treatment landscape for CCA, the Hippo pathway broadly, animal models of CCA with attention to Hippo-related models, and the current strategies for targeting YAP.

AB - Cholangiocarcinoma (CCA) has an increasing incidence and remains a difficult to treat malignancy. In a search for more effective treatment options, progress has been made in identifying molecular drivers of oncogenic signaling including IDH mutations and FGFR2 fusions. In addition, multiple investigators have identified increased activity of YAP, the effector protein of the Hippo pathway, in CCA. The Hippo pathway regulates organ size, cellular proliferation, and apoptosis via YAP, a transcriptional co-activator. Targeting of the pathway has been difficult due the lack of a dedicated cell-surface receptor. However, more recently, additional cross-regulatory pathways have been identified that are potentially targetable. In this review, we address the current treatment landscape for CCA, the Hippo pathway broadly, animal models of CCA with attention to Hippo-related models, and the current strategies for targeting YAP.

KW - Cholangiocarcinoma

KW - Hippo pathway

KW - Yes-associated protein

UR - http://www.scopus.com/inward/record.url?scp=85066235350&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85066235350&partnerID=8YFLogxK

U2 - 10.1007/s00535-019-01563-z

DO - 10.1007/s00535-019-01563-z

M3 - Review article

C2 - 30815737

AN - SCOPUS:85066235350

VL - 54

SP - 485

EP - 491

JO - Journal of Gastroenterology

JF - Journal of Gastroenterology

SN - 0944-1174

IS - 6

ER -